Scilex Holding (SCLXW) Current Assets (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Current Assets of $42.0 million in Q1 2026, up 9.42% quarter-over-quarter from $38.4 million in Q4 2025, and up 46.22% on a YoY basis from $28.7 million in Q1 2025.
Scilex Holding (SCLXW) Current Assets (2020 - 2026) Analysis & Trends
Scilex Holding's Current Assets history runs 7 years deep, the most recent figure standing at $42.0 million for Q1 2026.
- In Q1 2026, Current Assets rose 46.22% year-over-year to $42.0 million; the TTM figure through Mar 2026 stood at $42.0 million (up 46.22% YoY), while the FY2025 annual figure was $38.4 million, down 7.68% from the prior year.
- Current Assets was $42.0 million for Q1 2026 at Scilex Holding, up from $38.4 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $69.2 million in Q2 2023 to a low of $165749.0 in Q3 2022.
- Historically, Current Assets has averaged $31.3 million across 5 years, with a median of $33.7 million in 2025.
- The sharpest annual moves came in 2023 and 2025: Current Assets jumped 15273.25% in 2023, then slumped 58.63% in 2025.
- A 5-year view of Current Assets shows it stood at $29.6 million in 2022, then surged by 58.0% to $46.8 million in 2023, then declined by 11.19% to $41.5 million in 2024, then retreated by 7.68% to $38.4 million in 2025, then advanced by 9.42% to $42.0 million in 2026.
- The last three Current Assets figures came in at $42.0 million (Q1 2026), $38.4 million (Q4 2025), and $16.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 23.94 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 54.84 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 59.17 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 33.53 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 35.02 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 31.48 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 18.64 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 42.82 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 27.21 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 41.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.97 Mn |
| Dec 31, 2025 | 38.36 Mn |
| Sep 30, 2025 | 16.49 Mn |
| Jun 30, 2025 | 33.67 Mn |
| Mar 31, 2025 | 28.70 Mn |
| Dec 31, 2024 | 41.55 Mn |
| Sep 30, 2024 | 39.86 Mn |
| Jun 30, 2024 | 50.42 Mn |
| Mar 31, 2024 | 37.75 Mn |
| Dec 31, 2023 | 46.78 Mn |
| Sep 30, 2023 | 25.48 Mn |
| Jun 30, 2023 | 69.25 Mn |
| Mar 31, 2023 | 31.10 Mn |
| Dec 31, 2022 | 29.61 Mn |
| Sep 30, 2022 | 165,749.00 |
| Jun 30, 2022 | 612,848.00 |
| Mar 31, 2022 | 524,341.00 |
| Dec 31, 2021 | 23.00 Mn |
| Sep 30, 2021 | 232,178.00 |
| Jun 30, 2021 | 491,980.00 |